VITILIGO Clinical Trial
Official title:
Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo
This study aims to evaluate some differences in the immune system between patients with
vitiligo and patients without the disease.
These differences will be evaluated by the extraction of peripheral blood that will be
analyzed before the treatment and after the treatment that, in the habitual way and at the
discretion of the responsible dermatologist.
Patients agreeing to participate in the study will be subjected to extraction of two tubes
(20 ml) of peripheral blood (baseline) and after 12 weeks (+/- 5 days) of treatment.
Therefore, neither treatment nor follow-up visits will be modified by participation, but will
be the same whether or not participate in the study.
In the case of controls, two peripheral blood tubes (20ml) will be removed in a single
participation.
Patients with vitiligo will also be asked to complete questionnaires to measure stress,
depression and perception of disease (PSS-10, Skindex-29, HADS, Likert) before and after 12
weeks (+/- 5 days) of therapeutic intervention .
This study will include 20 patients with active non-segmental vitiligo and 10 controls
without the disease. The duration of participation in this study will be 12 weeks (+/- 5
days) for patients with vitiligo and a single participation (extraction of 20 ml of
peripheral venous blood) for the controls.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05298033 -
Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo
|
Phase 2 | |
| Recruiting |
NCT05872477 -
Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas
|
Phase 2 | |
| Terminated |
NCT04374435 -
Evaluating the Efficacy of the Melanocyte Keratinocyte Transplantation Procedure in the Treatment of Vitiligo
|
N/A | |
| Completed |
NCT04103060 -
Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo
|
Phase 2 | |
| Terminated |
NCT04271501 -
Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure for Repigmentation of Stable Vitiligo Lesions
|
N/A | |
| Completed |
NCT04530344 -
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
|
Phase 3 | |
| Not yet recruiting |
NCT05008887 -
Fractional CO2 Laser-assisted Cutaneous Delivery of Methotrexate Versus 5-fluorouracil in Stable Non-segmental Vitiligo
|
Phase 4 | |
| Terminated |
NCT02191748 -
Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo
|
Phase 2/Phase 3 | |
| Terminated |
NCT01262547 -
A New Micrografting Technique for Vitiligo
|
Phase 2 | |
| Completed |
NCT01382589 -
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo
|
Phase 2 | |
| Active, not recruiting |
NCT04971200 -
Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo
|
Early Phase 1 | |
| Completed |
NCT04872257 -
Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo
|
N/A | |
| Completed |
NCT04547998 -
Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions
|
N/A | |
| Not yet recruiting |
NCT04039451 -
Prevalence of Psoriasis and Vitiligo in Assiut Governorate, Egypt
|
||
| Not yet recruiting |
NCT03611348 -
Microneedling and Latanoprost in Acrofacial Vitiligo
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03199664 -
Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo
|
Phase 4 | |
| Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
| Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
| Recruiting |
NCT04246372 -
Tofacitinib for Immune Skin Conditions in Down Syndrome
|
Phase 2 | |
| Completed |
NCT02797574 -
Stress Response Pathways in Vitiligo
|
N/A |